East Side Clinical Laboratory Launches Blood Test that Detects Lung Cancer at its Earliest Stages of Development
(PRWEB) July 17, 2013 -- East Side Clinical Laboratory announced today that it has recently entered into an agreement with Oncimmune® USA LLC to offer EarlyCDT®-Lung. EarlyCDT-Lung is a simple blood test that aids physicians in the early detection of lung cancer.
EarlyCDT-Lung has been shown to detect early and late stage cancers in research studies as well as in clinical use. Oncimmune’s EarlyCDT® uses a panel of tumor antigens to diagnose autoantibodies (immuno-biomarkers) produced by the patient’s immune system when lung cancer is present. Elevation of any one of the autoantibodies in the test panel above a predetermined cut-off value suggests that a tumor might be present.
“We feel that because of our relationship with East Side Clinical Laboratory we are able to allow high risk individuals the best possible solution for the early detection of lung cancer in Rhode Island and parts of Massachusetts,” said Greg Stanley, Chief Commercial Officer at Oncimmune USA. “We believe we can improve the outlook and well-being for countless individuals by aiding physicians in diagnosing lung cancer at an earlier stage.”
Patient blood samples are analyzed at Oncimmune’s CLIA-certified laboratory. Nearly 2,000 physicians are using the test as well as numerous leading academic and medical institutions. Seventeen peer-reviewed publications support the EarlyCDT® autoantibody platform, click here. EarlyCDT-Lung has high specificity (93%), 7 times fewer false positives and 7 times better positive predictive value (PPV) than CT, and >91% accuracy, when considering a population with 2% prevalence of lung cancer (20 lung cancers per thousand). An audit of clinical data from the first 1,600 patients tested by EarlyCDT-Lung validates its utility to detect early stage lung cancer and its overall performance, click here. The Scottish government is conducting a 10,000 patient, randomized clinical trial to validate the economic benefit of the test in screening high-risk patients, click here.
Patient blood samples sent to East Side Clinical Laboratory will be analyzed at Oncimmune’s CLIA-certified laboratory located in De Soto, Kansas.
About East Side Clinical Laboratory
East Side Clinical Laboratory, Inc., an affiliate of Sonic Healthcare, established in 1949 and incorporated in the state of Rhode Island in 1979, is the State’s largest independent laboratory and a leading provider of laboratory services in the region. East Side, a full service laboratory, maintains a network of over 50 locations in RI and South Eastern MA serving a wide variety of clientele, including physicians, businesses, nursing and assisted living facilities.
About Oncimmune
Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune is a privately funded company located in Nottingham, UK with US headquarters and a CLIA-certified laboratory located just outside of Kansas City. The company launched a proprietary platform technology for early cancer detection, called EarlyCDT®. The first commercially available test, EarlyCDT®-Lung, a blood test to aid in the early detection of lung cancer, was released in 2009. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian.
Greg Stanley, Oncimmune, http://www.oncimmune.com, (317) 363-0071, [email protected]
Share this article